Updated 2020 guidelines for diagnosis and treatment of invasive aspergillosis in children with hematologic malignancy

Invasive aspergillosis (IA) is a major cause of morbidity in immunocompromised children. Patients with acute myeloid leukemia, relapsed acute luekemia and stem cells recipients are at high-risk for IA. Despite improving of diagnosis, prevention and treatment of IA mortality remains high. The main factors for favorable outcome of IA are early diagnosis and prompt appropriate treatment. Currently, few different international guidelines for IA have been developed but there are no Russian recommendations. An additional problem typical for Russia is poor level of microbiological diagnostic leading to underestimated frequency of IA or non-appropriate usage of antifungal drugs. This article presents an algorithm for diagnosis and treatment of IA in immunocompromised patient taking into account the characteristics of children with hematologic malignancy.

invasive aspergillosis, pediatric patients, hematologic malignancy, antifungal treatment